Skip to content
Open access

Immunoinformatics-guided design and in silico evaluation of BAFF- and APRIL-adjuvanted multi-epitope vaccine candidates against human metapneumovirus

Sep 2026 · Frontiers in Virology · 0 citations · 44 references

TL;DR

An immunoinformatics-guided reverse vaccinology approach to design novel BAFF- and APRIL-adjuvanted multi-epitope vaccine candidates against HMPV identified BAFF- and APRIL-containing multi-epitope constructs with favorable predicted antigenic, physicochemical, structural, and immunological characteristics that warrant further experimental investigation.

Abstract

Human metapneumovirus (HMPV) is a leading cause of acute respiratory tract infections in infants, older adults, and immunocompromised individuals; however, no licensed vaccine is currently available. This study employed an immunoinformatics-guided reverse vaccinology approach to design novel BAFF- and APRIL-adjuvanted multi-epitope vaccine candidates against HMPV. Major structural and non-structural HMPV proteins, including fusion (F), attachment glycoprotein (G), (matrix) M2-1, M2-2, phosphoprotein (P), nucleoprotein (N), small hydrophobic (SH), and RNA-dependent RNA polymerase (L) proteins, were screened for antigenicity. Cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), B-cell, and interferon-γ (IFN-γ)-inducing epitopes were predicted and evaluated for antigenicity, allergenicity, toxicity, and immunogenicity before being assembled into multi-epitope constructs using appropriate peptide linkers. BAFF and APRIL were incorporated as candidate immunomodulatory components based on their established roles in B-cell biology and humoral immune responses. The final vaccine constructs contained 24 selected epitopes (8 CTL, 8 HTL, and 8 B-cell epitopes) and demonstrated favorable predicted antigenicity, stability, hydrophilicity, thermostability, and non-allergenic and non-toxic properties. Secondary structure analysis revealed balanced proportions of α-helices, β-strands, and random coils, supporting structural stability and epitope accessibility. Molecular docking predicted putative interactions between the vaccine constructs and Toll-like receptors TLR1 and TLR4, with the predicted complexes exhibiting multiple intermolecular contacts at the receptor-ligand interfaces. These findings suggest structural compatibility between the vaccine constructs and the selected TLRs; however, functional receptor binding and activation require experimental validation. The in silico analyses identified BAFF- and APRIL-containing multi-epitope constructs with favorable predicted antigenic, physicochemical, structural, and immunological characteristics that warrant further experimental investigation. These computational findings provide a basis for prioritizing candidate constructs. Nevertheless, molecular dynamics simulations and in vitro and in vivo studies are required to validate the structural stability, immunogenicity, safety, and protective efficacy of the proposed vaccine candidates.

Read PDF

Similar papers

Open access Sep 2026

Immunoinformatics-Guided Design, Immunological Evaluation, and Macrophage Transcriptomic Profiling of a Multi-Epitope Vaccine Candidate Against Mycobacterium avium subsp. paratuberculosis

The designed MAP multi-epitope vaccine candidate was immunogenic in mice; the exploratory MYY-containing formulation showed numerically higher immune-response readouts in this experimental setting, although these differences were not statistically significant.

Zhi-Jie Luo, Zeng-Ke Wei, Jia-Luo Xu et al. · 0 citations
Aug 2026

In silico pharmacological evaluation of a multi-epitope vaccine candidate targeting the G1 and G2 glycoproteins of Oropouche virus via TLR3 interaction.

Findings indicate that the G1-based multi-epitope vaccine is a potential candidate for further experimental validation and may serve as an effective preventive strategy against OROV infection.

Khadija Khawar, Komal Imran, Muhammad Aamir Sharif et al. · 0 citations
Open access Sep 2026

Immunoinformatics-based design of a multi-epitope mRNA vaccine candidate targeting the major human-infecting hepatitis E virus genotypes 1–4

Background Hepatitis E virus (HEV) is one of the leading causes of acute and chronic hepatitis among humans across the globe and is linked to severe diseases in immunocompromised individuals and pregnant women. Despite its substantial global burden, only one vaccine is licensed (in China and Pakistan), limiting its glo...

Maham Mehrangaze Khonza, Zain Saeed, Zohra Jabeen et al. · 0 citations
Open access Sep 2026

Computationally guided multi-epitope vaccine design targeting oncoprotein BZLF1, EBNA1, LMP1, and LMP2 for of EBV associated gastric cancer

Epstein–Barr virus (EBV)–associated gastric cancer (EBVaGC) is distinct molecular subtype of gastric cancer for which effective preventive and targeted therapeutic strategies remain limited. This study aimed to design and evaluate multiepitope vaccine candidates targeting four EBV proteins critically involved in this d...

Elvin Delonio, Y. Ysrafil, Herlina Eka Shinta et al. · 0 citations
Open access Sep 2026

From Epitope Discovery to Immune Simulation: An Integrated Computational Strategy for Multi-Epitope Vaccine Design Against Human Mastadenovirus

Human Adenovirus (ADV), a member of the Adenoviridae family, is Double-Stranded DNA (DSDNA) virus associated with gastroenteritis, conjunctivitis, and severe respiratory infection and illnesses in infants and immunocompromised individuals. Despite its widespread prevalence in food and water sources, no specific and eff...

Arshad Iqbal · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.